NAD+ Precursors Revisited: NR, NMN, NADH, and NAD+ Injectables

NAD+ (nicotinamide adenine dinucleotide) is the central redox cofactor for sirtuins, PARPs, CD38, and oxidative phosphorylation, the cellular machinery for energy metabolism and longevity-relevant signalling. NAD+ levels decline approximately 50% between age 20 and 50. Raising NAD+ back toward youthful levels has become one of the most-funded ideas in the longevity space. The question is which precursor delivers the goods, at what dose, and whether the biomarker improvement translates into downstream benefit.

The salvage pathway

NAD+ is recycled through the salvage pathway from nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). Each precursor enters the pathway at a different point. NR converts to NMN via NRK1/NRK2 enzymes; NMN converts to NAD+ via NMNAT enzymes. Both eventually become NAD+, though through slightly different cellular handling.

Niacin (nicotinic acid) also raises NAD+ via a different pathway, but at therapeutic doses produces the famous niacin flush, which limits practical dosing. Tryptophan is the de novo precursor (kynurenine pathway → NAD+) but the yield is small and the pathway has psychiatric side-effect potential.

Nicotinamide riboside (NR)

NR was characterised as an NAD+ precursor by Charles Brenner in 2004. ChromaDex licensed the synthesis and branded it Niagen, which is the form in essentially every published NR trial.

Trammell 2016 demonstrated that 100-1000 mg NR raised blood NAD+ by 40-90% in healthy adults. Martens 2018 showed reduced blood pressure and arterial stiffness in middle-aged adults at 1 g/day over 6 weeks. Dollerup 2018 confirmed NAD+ elevation across multiple tissues. The biomarker evidence is the strongest in the NAD+ precursor space.

The downstream-clinical-benefit evidence is less convincing. Several RCTs have not shown clear cognitive or metabolic benefit despite NAD+ elevation. The simplest interpretation: raising NAD+ matters less in healthy younger adults whose baseline is still adequate; it matters more in older adults or those with metabolic disease.

Standard dose: 300-1000 mg per day, single morning dose, with or without food.

Nicotinamide mononucleotide (NMN)

NMN gained celebrity profile through David Sinclair's lab at Harvard. The biosynthetic case is that NMN is one step closer to NAD+ than NR, bypassing the NRK1/NRK2 enzymatic step.

Yoshino 2021 published the landmark Science paper showing improved aerobic capacity and skeletal muscle function in postmenopausal women at 250 mg/day. Multiple subsequent trials replicated NAD+ elevation. The compound's regulatory status has been turbulent in the US, the FDA briefly classified NMN as a drug rather than a supplement in 2022, then reversed under industry pressure.

Direct comparison with NR is hampered by the rarity of head-to-head trials. The available evidence suggests roughly comparable NAD+ elevation per mg, though the celebrity gap (Sinclair's NMN advocacy versus Brenner's NR development) drives the popular preference for NMN.

Standard dose: 250-1000 mg per day, single morning dose. Sublingual administration is marketed as more bioavailable; the actual pharmacokinetic data is mixed.

NADH (the reduced form)

NADH is the reduced state of NAD+, chemically related but not interchangeable. Some supplement vendors sell NADH directly with the claim that it bypasses the precursor pathway entirely.

The evidence base is small. Birkmayer 1996 demonstrated a small effect in Parkinson's; subsequent trials have not consistently replicated. The compound is unstable in the GI tract and bioavailability is poor, most ingested NADH degrades before absorption.

The "stabilized NADH" formulations attempt to address this but have limited published evidence supporting either bioavailability or downstream effect.

Standard dose: 5-10 mg per day, sublingual. Modest effect at best in most users.

NAD+ IV and injection

Some longevity-focused clinics offer direct NAD+ infusions or subcutaneous injections at 100-1000 mg per session. The pharmacokinetic case is that bypassing the GI tract delivers more NAD+ to tissue.

The evidence base for the IV protocol is limited to small open-label studies and clinical reports. The subjective effect is real for many users, a perceived energy and clarity lift in the days following infusion, but the long-term clinical benefit (versus oral precursors) is unclear.

The cost is high ($300-1000 per infusion) and the infusion itself can be uncomfortable. The intramuscular and subcutaneous routes are less established.

Whether IV NAD+ delivers meaningfully more benefit than the much cheaper oral precursors is an open question. The current evidence does not support strong claims either way.

What about niacinamide (nicotinamide)?

Plain niacinamide (nicotinamide, NAM) is the cheapest NAD+ precursor and a long-established vitamin (B3). It raises NAD+ similarly to NR and NMN.

The catch: at high doses, niacinamide inhibits sirtuin function, the very enzymes that NAD+ supplementation aims to support. The inhibition is dose-dependent and the threshold is debated, but the consensus is that doses above 500 mg/day may produce sirtuin inhibition.

Lower doses (50-250 mg/day) raise NAD+ without measurably inhibiting sirtuins, and at this dose niacinamide is by far the cheapest option. The catch is the celebrity branding, most retail consumers will pay 10-20x more for NR or NMN despite comparable NAD+ elevation at clinical doses.

The CD38 inhibitor combination

CD38 is an enzyme that consumes NAD+. CD38 expression increases with age, contributing to the NAD+ decline. Inhibiting CD38 reduces NAD+ consumption and amplifies the effect of any precursor.

Apigenin (the chamomile flavonoid) is the most-studied natural CD38 inhibitor. Quercetin has weaker CD38 effects. Some protocols pair NR or NMN with apigenin 50-100 mg to reduce the rate of NAD+ depletion.

The combination is rational mechanistically but not yet supported by direct human outcome trials. It's a reasonable add-on for users committed to the NAD+ longevity story.

Should you take it?

The honest assessment for healthy adults under 40: NAD+ precursors raise the biomarker but the clinical benefit evidence is thin. Cost-benefit is unclear.

For adults 40-60 with metabolic complaints (mild insulin resistance, low energy, declining athletic performance): the case is stronger. NR 500 mg/day or NMN 250-500 mg/day is reasonable.

For adults 60+: the strongest case. NAD+ decline is substantial by this age and precursor supplementation reliably raises levels. NR has the larger evidence base; NMN is reasonable but more expensive. Pair with apigenin if budget allows.

For pure longevity hopefuls: the biomarker improvement is real but the lifespan-extension translation in humans is unknown and unproven. Set expectations accordingly.

What this doesn't do

NAD+ precursors are not stimulants. They don't produce acute energy or focus effects. The benefit, if any, accumulates over weeks to months. Users expecting an immediate lift will be disappointed and may abandon the protocol before any structural benefit manifests.

NAD+ precursors also don't substitute for exercise, sleep, and dietary basics, these inputs all influence NAD+ levels directly. The most cost-effective NAD+ intervention for most people is intermittent fasting plus regular aerobic exercise, both of which raise endogenous NAD+ without supplementation.